Biodistribution and Dosimetry of Intraventricularly Administered 124I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors

Conclusion: PET imaging with 124I-omburtamab antibody administered intraventricularly allows for noninvasive estimation of dose to CSF and normal organs. High CSF-to-blood absorbed-dose ratios are noted, allowing for an improved therapeutic index to leptomeningeal disease and reduced systemic doses. PET imaging–based estimates were less variable and more reliable than CSF sample–based dosimetry.

Source: Journal of Nuclear Medicine - December 1, 2019 Category: Nuclear Medicine Authors: Pandit-Taskar, N., Zanzonico, P. B., Kramer, K., Grkovski, M., Fung, E. K., Shi, W., Zhang, Z., Lyashchenko, S. K., Fung, A. M., Pentlow, K. S., Carrasquillo, J. A., Lewis, J. S., Larson, S. M., Cheung, N.-K. V., Humm, J. L. Tags: Clinical Source Type: research